In:
Journal of Viral Hepatitis, Wiley, Vol. 27, No. 7 ( 2020-07), p. 690-698
Abstract:
The impact of direct‐acting antiviral (DAA) therapies on fibrosis regression remains uncertain. In the current study, we prospectively evaluated dynamics of liver stiffness by transient elastography (TE) in patients with chronic HCV infection receiving DAA‐based treatment. Patients (260) were enrolled in the German Hepatitis C‐Registry (DHC‐R), a national multicentre real‐world cohort. Liver stiffness (LS) was assessed at baseline, end of treatment (EOT) and 24 weeks after EOT (FU24) by TE. Biochemical, virological and clinical data were obtained in parallel. In patients with SVR, there was a significant improvement of LS between baseline (median [range], 8.6 [1.7‐73.5] kPa) and FU24 (7.9 [1.7‐75 kPa]; P 〈 .0001) as well as between EOT (8.4 [1.7‐73.5 kPa]) and FU24 [ P 〈 .0001]. Stratified by fibrosis stage, patients classified into F4 had higher magnitude of LS reduction between BL (median [range] , 25.1 [13.5‐73.5] kPa) and FU24 (21.5 [3.1‐75] kPa; P = .002) compared to those with F2‐F3 (8.9 [7.1‐12.4] kPa and 8.8 [4.2‐29.1] ; P = .060) or F0‐F1 (5.3 [1.7‐7] kPa and 5.2 [1.7‐7.7] ; P = .064). In cirrhotic patients, low platelets were significantly associated with lack of liver stiffness improvement, both at EOT ( P = .018) and at FU24 ( P = .012). LS significantly correlated with ALT ( r = .371), AST ( r = .552), platelets ( r = −.499), GGT ( r = .250), bilirubin ( r = .230), APRI score ( r = .512), FIB‐4 score ( r = .517) and FORNS index ( r = .562); P 〈 .0001. Liver elastography improved significantly in our real‐world cohort after DAA‐based therapy. As LS correlates similarly with transaminase levels and serum fibrosis markers, it might reflect both reduction of necroinflammation and fibrosis regression.
Type of Medium:
Online Resource
ISSN:
1352-0504
,
1365-2893
Language:
English
Publisher:
Wiley
Publication Date:
2020
detail.hit.zdb_id:
1212497-7
detail.hit.zdb_id:
2007924-2
